Study Details

General Information

Boehringer Ingelheim DM2 1264.3

A randomised, double-blind parallel group study to compare the efficacy and safety of initial combination therapy with linagliptin 5 mg + pioglitazone 15 mg, 30 mg, or 45 mg, vs. monotherapy with pioglitazone (15 mg, 30 mg, or 45 mg) or linagliptin 5 mg once daily for 30 weeks, followed by a 54 week blinded trial period on linagliptin 5 mg + pioglitazone 30 or 45 mg versus pioglitazone monotherapy 30 or 45 mg or linagliptin 5 mg in type 2 diabetic patients with insufficient glycaemic control on

Protocol
Identifier1264.3 Site Number 01078
UIDc93ee6ab-9eb4-4fe8-8542-5b784a9b46be
StatusDone - Archived
Phase3
CategoryDiabetes Type 2 / Adult
Launch Year2011
NCT Number-
Created2011-03-24 16:30
Last Updated2011-03-24 16:30

Description

No description provided.

Comment

No comment.

Target Dates

NameDateRequired
Enrollment ClosedNo
Enrollment OpenNo
First Patient First VisitNo
Site Initiation Mtg.2011-07-20No
PI Meeting StartNo
PI Meeting EndNo
PI Meeting ArrivalNo
PI Meeting DepartureNo
Closeout Date2013-07-03No
Final PatientVisitNo
PreStudy Selection VisitNo
Target Date 12No
Target Date 13No
Target Date 14No

Leadership

RoleStaffLoginRequired
PrincipalUnger, JeffreyJUngerNo
Recruiter-No
CoordinatorMata, NellyNMataNo
RegulatoryAguirre, SandraSAguirreNo

Custom Fields

No custom fields.

Sponsor & Organization

SponsorBoehringer Ingelheim Pharmaceuticals, Inc.
DivisionBoehringer Ingelheim Pharmaceuticals
TeamBoehringer Ingelheim Pharmaceuticals
Managing SiteCatalina Research Institute, LLC
Organization

Contacts

IRB RefCIRBI Webportal access ONLY
CRO
CRO Ref
Correspondence0

Opportunity

Probability0
Comment
Status ColorGainsboro
Currency-
Mayra Sibley

2 Hours

Hi there, I'm Jesse and you?
You

3 minutes

My name is Anne Clarc.
Mayra Sibley

40 seconds

Nice to meet you Anne.
How can i help you?